Lipids in Health and Disease · 2013 · 33 citations · 19 references
PharmacyCardiologyPharmacotherapyCardiovascular PharmacotherapyLipid BiochemistryRabbit MedicineAtherosclerosis PharmacotherapyCardiovascular DiseaseLipid-lowering TherapyRabbit PharmacologyAtherosclerosis Molecular MechanismsAtherosclerotic Lipid AccumulationAtherosclerotic ProgressionLow-density Lipoprotein Cholesterol ReductionPlasma Cholesterol Levels
BACKGROUND: Probucol and statin are often prescribed for treating atherosclerosis. These two drugs exhibit different mechanisms but it is unknown whether they have the same anti-atherogenic properties. In the current study, we examined whether these two drugs at optimal doses could inhibit the initiation of atherosclerosis in cholesterol-fed rabbits in the same way. METHODS: New Zealand White rabbits were fed a cholesterol-rich diet for 5 weeks to produce the early-stage lesions of atherosclerosis. Drug-treated rabbits were administered either probucol or atorvastatin and serum lipids and aortic atherosclerotic lesions were compared with those in a control group. RESULTS: Atorvastatin treatment significantly reduced serum total cholesterol levels while probucol treatment led to significant reduction of high-density lipoprotein cholesterol levels without changing total cholesterol levels compared with those in the control group. Compared with the control, probucol treatment led to 65% (p < 0.01) reduction while atorvastatin treatment led to 23% (p = 0.426) reduction of the aortic lesion area. Histological and immunohistochemical analyses revealed that the lesions of the probucol-treated group were characterized by remarkable reduction of monocyte adherence to endothelial cells and macrophage accumulation in the intima compared with those of both atorvastatin and control groups. Furthermore, low-density lipoprotein (LDL) isolated from the probucol group exhibited prominent anti-oxidative reaction, which was not present in LDL isolated from either the atorvastatin-treated or the control group. CONCLUSIONS: This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima. Anti-oxidization of LDL by probucol protects more effectively against early-stage lesion formation than statin-mediated lipid-lowering effects.
19
Frederick T. Hatch, Robert S. Lees · Advances in lipid research · 1968 · 1.2K citations
T. Kita, Yukio Nagano, Masataka Yokode et al. · Proceedings of the National Academy of Sciences · 1987 · 878 citations · Full text
Shinichi Usui, Yukichi Hara, Seijin Hosaki et al. · Journal of Lipid Research · 2002 · 333 citations · Full text
Life Sciences, Pharmaceutical Analysis, Analytical Chemistry +16